References
- Ahmed M.S., Abed M., Voelkl J., Lang F.: Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfate. BMC Nephrol. 14, 244 (2013)
- Anders H.J., Andersen K., Stecher B.: The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 83, 1010–1016 (2013)
- Arumugam M., Bork P. et al.: Enterotypes of the human gut microbiome. Nature 473, 174–180 (2011)
- Baeckhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., Semenkovich C.F., Gordon J.I.: The gut microbiota as an environmental factor that regulates fat storage. Proc Nati Acad Sci USA,101,15718–15723(2004)
- Baumgart D.C., Dignass A.U.: Intestinal barrier function. Currt Opin Clinl Nutr Metab Care. 5, 685–694 (2002)
- Bossola M., Luciani G., Rosa F., Tazza L.: Appetite and Gastrointestinal Symptoms in Chronic Hemodialysis Patients. J. Renl. Nutr. 21, 448–454 (2011)
- Carrero J.J., Stenvinkel P.: Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin. J. Am. Soc. Nephrol. 4, 49–55 (2009)
- Castillo-Rodriguez E., Sanchez-Niño M.D. et al.: Impact of altered intestinal microbiota on chronic kidney disease progression. Toxins, 10, doi: 10.3390/toxins10070300 (2018)
- Claro L.M., Pécoits-Filho R. et al.: The impact of uremic toxicity induced inflammatory response on the cardiovascular burden in chronic kidney disease. Toxins, 10, doi: 10.3390/toxins10100384 (2018)
- Costea P.I., Bork P. et al.: Enterotypes in the landscape of gut microbial community composition. Nat. Microbiol. 3, 8–16 (2018)
- Cummings J.H., Macfarlane G.T.: Collaborative JPEN-Clinical Nutrition Scientific Publications Role of intestinal bacteria in nutrient metabolism. JPEN-Parenter Enter. 21, 357–365 (1997)
- DeFronzo R.A., Alvestrand A., Smith D., Hendler R., Hendler E., Wahren J.: Insulin resistance in uremia. J. Clin. Invest. 67, 563–568 (1981)
- Doron S., Snydman D.R.: Risk and Safety of Probiotics. Clin. Infect. Dis. 60, 129–34 (2015)
- Esgalhado M., Kemp J.A., Damasceno N.R., Fouque D., Mafra D.: Short-chain fatty acids: a link between prebiotics and microbiota in chronic kidney disease. Future Microbiol. 12, 1413–1425 (2017)
- Fujii H., Goto S., Fukagawa M.: Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins, 10, doi: 10.3390/toxins10050202 (2018)
- George Kerry R., Patra J.K., Gouda S., Park Y., Shin H.S., Das G.: Benefaction of probiotics for human health: A review. J. Food Drug. Anal. 26, 927–939 (2018)
- Gerson L.B.: Causes of gastrointestinal hemorrhage in patients with chronic renal failure. Gastroenterology 145, 895–897 (2013)
- Goto S., Fujii H., Hamada Y., Yoshiya K., Fukagawa M.: Association Between Indoxyl Sulfate and Skeletal Resistance in Hemodialysis Patients. Ther. Apher. Dial. 14, 417–423 (2010)
- Cigarran Guldris S., Gonzalez Parra E., Cases Amenós A.: Gut microbiota in chronic kidney disease. Nefrología (English Edition) 37, 9–19 (2017)
- Hoyles L., Dumas M.E. et al.: Metabolic retroconversion of tri-methylamine N-oxide and the gut microbiota. Microbiome 6, 73 (2018)
- Hsu C.C., Lu Y.C., Chiu C.A., Yu T.H., Hung W.C., Wang C.P., Lu L.F., Chung F.M., Lee Y.J., Tsai I.T: Levels of indoxyl sulfate are associated with severity of coronary atherosclerosis. Clin. Invest. Med. 36, E42–49 (2013)
- Jia L., Jia Q., Yang J., Jia R., Zhang H.; Efficacy of probiotics supplementation on chronic kidney disease: a systematic review and meta-analysis. Kidney Blood Press. Res 43,1623–1635 (2018)
- Kelly J.T., Palmer S.C., Wai S.N., Ruospo M., Carrero J.J., Campbell K.L., Strippoli G.F.M.: Healthy dietary patterns and risk of mortality and ESRD in CKD: A meta-analysis of cohort studies. Clin. J. Am. Soc. Nephrol. 12, 272–279 (2017)
- Koppe L., Fouque D., Soulage C.O.: The role of gut microbiota and diet on uremic retention solutes production in the context of chronic kidney disease. Toxins, 10, doi: 10.3390/toxins10040155 (2018)
- Koppe L., Mafra D., Fouque D.: Probiotics and chronic kidney disease. Kidney Int. 88, 958–966 (2015)
- Koppe L., Pelletier C.C., Alix P.M., Kalbacher E., Fouque D., Soulage C.O., Guebre-Egziabher F.: Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol. Dial. Transplant 29, 1666–1674 (2014)
- Koppe L., Soulage C.O. et al.: p-Cresyl sulfate promotes insulin resistance associated with CKD. J. Am. Soc. Nephrol. 24, 88–99 (2013)
- Leong S.C., Sirich T.L.: Indoxyl Sulfate-review of toxicity and therapeutic strategies. Toxins 8, E358 (2016)
- Ley R.E., Bäckhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I.: Obesity alters gut microbial ecology. Proc. Nat. Acad. Sci. USA 102, 11070–11075 (2005)
- Lin C.J., Wu V., Wu P.C., Wu, C.J.: Meta-Analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS One 10, e0132589 (2015)
- Liu B., Luo F., Luo X., Duan S., Gong Z., Peng J.: Metabolic enzyme system and transport pathways in chronic kidney diseases. Curr. Drug. Metab. 19, 568–576 (2018)
- McCaleb M.L., Izzo M.S., Lockwood D.H.: Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J. Clin. Invest. 75, 391–396 (1985)
- Meijers B., Farré R., Dejongh S., Vicario M., Evenepoel P.: Intestinal barrier function in chronic kidney disease. Toxins, 10, doi: 10.3390/toxins10070298 (2018)
- Meropol S.B., Edwards A.: Development of the infant intestinal microbiome: a bird’s eye view of a complex process. Birth Defects Res. C Embryo. Today 105, 228–239 (2015)
- Mishima E., Abe T. et al.: Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am. J. Physiol. Renal Physiol. 315, F824–833 (2018)
- Moraes C., Borges N.A., Mafra D.: Resistant starch for modulation of gut microbiota: Promising adjuvant therapy for chronic kidney disease patients?. Eur. J. Nut. 55, 1813–1821 (2016)
- Nallu A., Sharma S., Ramezani A., Muralidharan J., Raj D.: Gut microbiome in CKD: challenges and opportunities. Transl. Res. 179, 24–37 (2017)
- Nangaku M., Mimura I., Yamaguchi J., Higashijima Y., Wada T., Tanaka T.: Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients. J. Ren. Nutr. 25, 160–163 (2015)
- Pan W., Kang, Y.: Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. Int. Urol. Nephrol. 50, 289–299 (2018)
- Pawlak, J., Derlacz R.A.: Mechanizm powstawania oporności na insulinę w tkankach obwodowych. Postępy Biochemii 57, 200–206 (2011)
- Piñero-Lambea C., Ruano-Gallego D., Fernández L.Á.: Engineered bacteria as therapeutic agents. Curr. Opin. Biotechnol. 35, 94–102 (2015)
- Poesen R., Evenepoel P., De Loor H., Delcour J.A., Courtin C.M., Kuypers D., Augustijns P., Verbeke K., Meijers B.: The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS One 11, e0153893(2016)
- Prokopienko A.J., Nolin T.D.: Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease. Expert Rev. Clin. Pharmacol. 11, 71–82 (2018)
- Qin, J., Wang J. et al.: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010)
- Krishnamurthy V.M., Wei G., Baird B.C., Murtaugh M., Chonchol M.B., Raphael K.L., Greene T., Beddhu S.: High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int. 81, 300–306 (2012)
- Rhee E.P., Gerszten R.E. et al.: A combined epidemiologic and metabolomic approach improves CKD prediction, J. Am. Soc. Nephrol. 24, 1330–1338 (2013)
- Rigalleau V., Blanchetier V., Combe C., Guillot C., Deleris G., Aubertin J., Aparicio M., Gin H.: A low-protein diet improves insulin sensitivity of endogenous glucose production in predialytic uremic patients. Am. J. Clin. Nutr. 65, 1512–1516 (1997)
- Sabatino A., Regolisti G., Brusasco I., Cabassi A., Morabito S., Fiaccadori E.: Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol. Dial. Transplant. 30, 924–933 (2015)
- Salmean Y.A., Segal M.S., Langkamp-Henken B., Canales M.T., Zello G.A., Dahl W.J.: Foods with added fiber lower serum creatinine levels in patients with chronic kidney disease. J. Ren. Nutr. 23, e29–32 (2013)
- Sato B., Murohara T. et al.: Relation of plasma indoxyl sulfate levels and estimated glomerular filtration rate to left ventricular diastolic dysfunction. Am. J. Cardiol. 111, 712–716 (2013)
- Sircana A., De Michieli F., Parente R., Framarin L., Leone N., Berrutti M., Paschetta E., Bongiovanni D., Musso G.: Gut microbiota, hypertension and chronic kidney disease: recent advances. Pharmacol. Res. doi: 10.1016/j.phrs.2018.01.013 (2018)
- Soulage C.O., Koppe L., Fouque D.: Protein-bound uremic toxins... new targets to prevent insulin resistance and dysmetabolism in patients with chronic kidney disease. J. Ren. Nutr. 23, 464–466 (2013)
- Spoto B., Pisano A., Zoccali C.: Insulin resistance in chronic kidney disease: a systematic review. Am. J. Physiol. Renal. Physiol. 311, 1087–1108 (2016)
- Strzępa A., Szczepanik M.: Wpływ naturalnej flory jelitowej na odpowiedź immunologiczną. Postepy Hig. Med. Dosw. 67, 908–920 (2013)
- Tojo R., Suarez A., Clemente M.G., de los Reyes-Gavilan C.G., Margolles A., Gueimonde M., Ruas-Madiedo P.: Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis. World J. Gastroenterol. 20, 15163–15176 (2014)
- Tsai M.L., Hsieh I.C., Hung C.C., Chen C.C.: Serum free indoxyl sulfate associated with in-stent restenosis after coronary artery stentings. Cardiovasc. Toxicol. 15, 52–60 (2015)
- Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I.: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006)
- Vaziri N.D., Goshtasbi N., Yuan J., Jellbauer S., Moradi H., Raffatellu M., Kalantar-Zadeh K.: Uremic Plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am. J. Nephrol. 36, 438–443 (2012)
- Vaziri N.D., Yuan J., Norris K.: Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am. J. Nephrol. 37, 1–6 (2013)
- Velasquez M.T., Centron P., Barrows I., Dwivedi R., Raj D.S.: Gut microbiota and cardiovascular uremic toxicities. Toxins, 10, doi: 10.3390/toxins10070287 (2018)
- Watanabe K., Tominari T., Hirata M., Matsumoto C., Hirata J., Murphy G., Nagase H., Miyaura C., Inada M.: Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. FEBS Open Bio 7, 1178–1185 (2017)
- Wong J., Piceno Y.M., DeSantis T.Z., Pahl M., Andersen G.L., Vaziri, N.D.: Expansion of Urease – and uricase-containing, indole – and p-Cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 9, 230–237 (2014)
- Yacoub R., Kaji D., Patel S.N., Simoes P.K., Busayavalasa D., Nadkarni G.N., He J.C., Coca S.G., Uribarri J.: Association between probiotic and yogurt consumption and kidney disease: insights from NHANES. Nutr. J. 15, 10 (2016)
- Zhuang L., Chen H., Zhang S., Zhuang J., Li Q., Feng Z.: Intestinal Microbiota in Early Life and Its Implications on Childhood Health. Genomics Proteomics Bioinformatics, DOI: 10.1016/j.gpb.2018.10.002